In 1992 two Spanish cardiologist brothers, Pedro and Josep Brugada reported eight patients with aborted cardiac arrest and no demonstrable heart disease who exhibited in sinus rhythm right bundle branch block (RBBB) with prominent STsegment elevation in precordial leads V 1 -V 3 .
1 Despite initial controversy about the diagnosis, especially concerning the possibility of a subtle arrhythmogenic right ventricular dysplasia, the repeated lack of right ventricular involvement along with consistent clinical, electrocardiographic (ECG), and electrophysiological features convinced the cardiological community that the Brugada syndrome was actually a new and important cause of sudden cardiac death (SCD) in ostensibly healthy patients. 2 During the last decade an increased awareness among physicians has resulted in a growing number of patients reported worldwide. In 1998, Chen et al. 3 were first to establish that the Brugada syndrome was a genetic disease with an autosomal dominant pattern of transmission. These investigators described mutations all affecting the cardiac sodium channel SCN5A on chromosome 3. More recently, a novel gene locus on chromosome 3, distinct from SCN5A has been identified. 4 The genetic pattern of transmission of the disease has lead to the increased detection of asymptomatic patients affected by the disease among families of cardiac arrest survivors. [3] [4] [5] Despite the major advances accomplished during the last decade, there are still unanswered issues dealing with the clinical and genetic diagnosis of the Brugada syndrome and with its management. In the September 2001 issue of the European Heart Journal 6 appeared an article, "Task Force on Sudden Cardiac Death of the European Society of Cardiology," to which European and American experts contributed. Since several of the leading specialists of the Brugada syndrome (namely Drs. Sylvia Priori and Pedro Brugada) were active members of this task force, the conclusions reported on the management of the syndrome have a paramount importance. The conclusion of the task force was as follows: "Some investigators 2 supported the view that both symptomatic patients (syncopal episodes or aborted SCD) and asymptomatic patients who are inducible by programmed electrical stimulation are best managed by the implantation of an implantable cardioverter defibrillator (ICD). However, more recent data, 5 supported the view that given the low predictive accuracy of programmed electrical stimulation, cardiac arrest survivors and patients with a history of syncope or a family history of juvenile SCD should receive an ICD. Management of asymptomatic patients is still debated and no conclusive evidence exists to guide risk stratification in this subgroup. No drug has shown efficacy in the prevention of SCD."
At the time of writing the present article (February 2002), the authors' opinion concerning the management of the Brugada syndrome is somewhat different from that expressed in the Task Force of the European Society of Cardiology, especially regarding the role of antiarrhythmic drug therapy. This article presents the view of the current authors on the management of the Brugada syndrome including the group of symptomatic patients (cardiac arrest survivors or syncope) and the group of asymptomatic high risk patients with the Brugada-type ECG.
SCD Survivors and Syncopal Patients
Most electrophysiologists worldwide considered these patients as ideal candidates for ICD. Their recommendation is based on the following arguments: (1) After an initial arrhythmic event (cardiac arrest or syncope), approximately . 60% of symptomatic patients will have a recurrent arrhythmic event in the 4 years after the initial event 7, 8 ; (2) Before discussing these arguments in more detail, it is worth noting that although a large number of trials have demonstrated the superiority of ICD therapy versus medical therapy in decreasing mortality in survivors of cardiac arrest associated with heart disease, 10 there have been so far no published randomized studies comparing ICD versus drug therapy in patients with idiopathic VF or the Brugada syndrome.
ICD Therapy

Efficacy
No one argues the exceptional efficacy of ICD for terminating VF. Actually, the authors are not aware of a single case of death occurring in a patient with the Brugada syndrome treated with an ICD. Chalvidan et al. 11 reported a case of near-fatal electrical storm in a patient with an ICD, but the patient subsequently fully recovered. In addition, there is no doubt that most patients who have experienced the trauma of cardiac arrest will feel a greater sense of security after an ICD is implanted.
Limitations
Several limitations do exist regarding the use of an ICD. (1) Since the patient is usually left without prophylactic drug therapy, she/he is at risk for recurrent ventricular tachyarrhythmias and subsequent discharges from the device. This may have deleterious consequences, for example, if the arrhythmia occurs while driving or during professionally exposed activities. (2) Electrical storms of VF and polymorphic ventricular tachycardia (PVT) occurring within a few hours are not infrequently observed in the Brugada syndrome. [11] [12] [13] [14] Arrhythmic storms may lead to multiple ICD discharges with various consequences: need for emergency hospitalization, psychological disorders, 15 proarrhythmia, 16 deleterious effect on cardiac function, 17 electromechanical dissociation, 18 and even death. 19 (3) Although the incidence of ICD related complications is low, it is far from nil. Complications like lead dislodgment, device malfunction, device migration, inappropriate device discharges, vein thrombosis may occur. 20 The risk of early or late infection (pocket, electrode, or both) may reach 4%. 21 Moreover, assessment of the incidence of long-term complications is mainly derived from the analysis of patients after ICD implantation for malignant arrhythmias in the setting of organic heart disease. These patients are older and have more frequent comorbidity and a significantly higher risk for nonarrhythmic cardiac death than patients with Brugada syndrome. It is likely that data on the long-term complications of ICD gathered from patients with organic heart disease actually underestimates the longterm risk for ICD related complications in patients with Brugada syndrome who are younger. Studies of the long-term complications of ICD in patients with Brugada syndrome are not available yet. These patients are estimated to have a normal life expectancy and, therefore, are expected to undergo multiple device replacements and lead extractions during their life. This is an important issue, especially for young patients, like the 6-month-old Japanese infant reported by Suzuki et al. 13 or the 14-month-old girl reported by Priori et al. 22 In such young patients, a significant morbidity ought to be expected with ICD during longterm despite the constant miniaturization of the devices. (4) Dynamic variations in electrophysiological phenomena inherent to the Brugada syndrome may also complicate ICD therapy. Stix et al. 23 recently showed in two of three patients with Brugada syndrome that spontaneous or ajmaline induced changes in the surface ECG could be paralleled by significant variations in the right ventricular endocardial electrogram that may result in ICD malfunction. In such patients, implantation of a left ventricular epicardial lead for sensing and pacing could be required to avoid inappropriate tachycardia detection. (5) Finally, psychological problems may affect the ICD patient. For example, some patients (especially the young) may feel vulnerable and fearful of the device in case of frequent appropriate or inappropriate device discharges, repeated hospitalizations, or multiple surgical procedures. In addition, others may fear the aesthetic consequences of device implantation or the possible deleterious consequences in their ability to perform sportive activities.
Pharmacologic Therapy
Efficacy
In 1987 the authors' group was the first to report the efficacy of Class 1A antiarrhythmic agents in preventing induction of sustained PVT in the electrophysiological laboratory in a small group of five patients with apparently idiopathic VF.
type ECG (an entity described only in 1992). In a study including 34 patients with idiopathic VF (29 patients without and 5 with the Brugada syndrome), they found that Class 1A antiarrhythmic drugs (mainly quinidine) effectively prevented arrhythmia induction in 4 (80%) of 5 and in 22 (100%) of 22 patients with and without the Brugada syndrome, respectively. 25 Of note is that two of the quinidine-responder patients in that study, who were initially classified as "idiopathic VF without Brugada syndrome," eventually developed a Brugada ECG-type after 14 and 15 years on quinidine therapy. Thus, their updated results show an acute electrophysiological efficacy of Class 1A antiarrhythmic agents in six (86%) of seven cardiac arrest survivors of Brugada syndrome. During a follow-up ranging from 60 to 201 (mean 125 6 66) months, five of these six patients were treated with quinidine based on the results of electrophysiological testing and have remained asymptomatic; the remaining drug-responder patient received an ICD due to drug intolerance. Finally, their experience also includes a cardiac arrest survivor patient with Brugada syndrome who received an ICD without prior electrophysiological study. After he suffered multiple VF episodes terminated by the ICD, quinidine therapy was started and the patient has remained asymptomatic during a 35-month follow-up.
Isolated cases of the high efficacy of quinidine in symptomatic patients with the Brugada syndrome have also been reported by others 13, 26 and a similarly beneficial effect of disopyramide has been reported in one patient. 27 In addition, Alings et al. 28 reported for the first time normalization of right precordial J waves and ST-segment elevation following oral administration of quinidine in two patients with Brugada syndrome (including one cardiac arrest survivor).
The beneficial results observed with Class 1A antiarrhythmic agents markedly contrast with the results observed with a wide variety of other antiarrhythmic drugs. In a review of the published literature including 104 symptomatic patients with Brugada syndrome (VF and syncope in 76 and 28 patients, respectively), Alings and Wilde 29 concluded that no particular antiarrhythmic drug seemed useful in preventing new episodes of VF. They found that arrhythmic events recurred in 9 (30%) of 30 patients treated with a b-adrenergic blocker (n 5 9), amiodarone (n 5 4), flecainide (n 5 1), a combination of b-adrenergic blocker with amiodarone (n 5 15) or an alpha-blocker (n 5 1). More recently, at the 2001 meeting of the American Heart Association, Nademanee et al. reported the preliminary results of a randomized study of 61 Thai patients with Brugada syndrome who had survived a sudden death episode or had the identifiable ECG pattern. These patients were randomized to either b-blocker or to single chamber ICD. A SCD event was observed in 11 (18%) of their patients, 7 in the ICD group and 4 in the medically treated group. The four patients in the b-blocker arm died as a result, while the ICD saved the lives of the remaining seven patients in the ICD arm of the trial. However, one could wonder about the clinical importance of this study since b-blocker agents are well known to worsen the Brugada syndrome. 30 
Electrophysiological Basis
The ECG sign of the Brugada syndrome is dynamic and often concealed, but can be readily unmasked by potent sodium channel blockers like flecainide, ajmaline, procainamide, and psilicainide (Fig. 1B) . 31 In general, the effectiveness of sodium channel blockers to unmask the syndrome is inversely proportional to the rate at which the drug dissociates from the sodium channel. 32 Class IC antiarrhythmics (flecainide) dissociate from the sodium channel most slowly, display the greatest use dependent block of the sodium channel current (I Na ), and are most effective in elevating the ST segment in Brugada patients, thus creating the substrate for the development of phase two reentrant extrasystoles and polymorphic VT. Class IA agents (disopyramide, procainamide) dissociate more rapidly than IC agents, display less use dependent block of I Na , and are less effective in elevating the ST segment. Because the presence of a prominent transient outward current (I to ) is at the heart of the mechanism thought to give rise to the Brugada syndrome, agents that inhibit this current can normalize the ST segment and thus exert an antiarrhythmic effect. [33] [34] [35] Thus, Class IA agents that inhibit I to in addition to I Na (e.g., quinidine) may exert an opposite effect, leading to normalization of the ST segment and possibly elimination of the arrhythmogenic substrate (Fig. 1C) . 25, 28 While disopyramide, a Class IA antiarrhythmic agent, also inhibits I to , it is less potent than quinidine in doing so. 36 Consequently, it may exert an antiarrhythmic or proarrhythmic action depending on heart rate and other prevailing conditions. It is noteworthy, that the anticholinergic effect of quinidine and disopyramide might contribute to their antiarrhythmic efficacy in the Brugada syndrome. 37 Class IB agents, which display little use dependence due to rapid dissociation from the sodium channel, are not at all effective in unmasking the Brugada syndrome. Although a cardioselective and ion channel-specific I to blocker does not exist, quinidine is the only agent available worldwide capable of exerting significant block of this current. The drug's effectiveness in the Brugada syndrome is limited by its actions to BELHASSEN, ET AL.
Figure 1. Twelve-lead electrocardiogram (ECG) tracings in an asymptomatic 26-year-old man with a Brugada sign: (A) during control: a "saddle-type" ST-segment elevation is observed in V 2 ; (B) after intravenous administration of 750 mg procainamide, the "saddle-type" ST-segment elevation changed into a "coved-type"; and © a few days after oral administration of quinidine bisulfate (1,500 mg/day, serum quinidine level 2.6 mg/L), marked attenuation of the ST-segment elevation is noted in right precordial leads. Note that ventricular fibrillation could be induced with double ventricular extrastimulation both during control and procainamide infusion. In contrast, only a few repetitive ventricular complexes could be induced during quinidine therapy using an aggressive protocol using quadruple ventricular extrastimulation. This patient has remained asymptomatic during quinidine therapy during a 12-month follow-up.
simultaneously block I Na . Another agent, tedisamil, currently in clinical trials for the treatment of atrial fibrillation also blocks I to in additional to other potassium channels, but it does it without significant block of (I Na ). 38 Quinidine and tedisamil are effective in normalizing the ST segment and preventing the development of arrhythmias in experimental models of the Brugada syndrome.
33,35
Advantages
Class 1A antiarrhythmic drug therapy offers several advantages for patients with Brugada syndrome. First, in contrast to ICD that treats the arrhythmic events, these medications are hopefully expected to prevent their occurrence. The patient treated with effective drug therapy should enjoy a normal life with a substantial reduced rate of hospitalization. Second, the relatively low cost of long-term antiarrhythmic therapy with quinidine makes it available for most medical systems worldwide. In this regard, it is important to note that the Brugada syndrome seems to be more frequent in Southeast Asia, 35 especially in some developing countries where the high cost of ICD therapy is unaffordable. Third, the high inducibility rate of sustained PVT/VF in patients with symptomatic Brugada syndrome, ranging from 73% 39 to 83% 8 according to Brugada et al., renders the option of electrophysiologically guided therapy with quinidine a valuable one for many patients. Fourth, antiarrhythmic therapy may be used as a "bridge" to ICD. This may be especially suitable in the very young patients.
Limitations
There are also several limitations to the use of antiarrhythmic therapy. First, electrophysiologically guided antiarrhythmic therapy requires baseline inducibility (preferably in a reproducible manner) of sustained ventricular tachyarrhythmias with programmed ventricular stimulation. Although the inducibility rate observed by Brugada et al. 8 in a large group of symptomatic patients (cardiac arrest survivors and syncope) was relatively high (83%), the authors believe that it can be further enhanced by the use of a stimulation protocol like the one used in their laboratory. This protocol uses a stimulus current intensity of five times diastolic threshold (but never . 3 mA) along with the use of repetition (5-10 times) of double and triple extrastimulation at the shortest coupling intervals that result in ventricular capture. 40 Using such a protocol, the authors observed a 100% inducibility rate of sustained ventricular tachyarrhythmias in a small group of six cardiac arrest survivors. Second, an excellent patient compliance to medications is required. Early detection of patients with low drug compliance may be difficult, especially during the hospitalization period following the cardiac arrest. Late detection (sometimes years after the arrhythmic event) can raise serious problems, and there were a few patients who refused the ICD therapy option following several uneventful years despite the partial or absent drug therapy. In this regard, it was noted that most patients who have done well for years on antiarrhythmic medications refused the ICD therapy option after they have received objective information of the advantages and disadvantages of the ICD. Third, an excellent patient tolerance to medications is imperative. In the authors' experience, about 15-20% of patients will manifest drug related side effects requiring drug discontinuation, but this will usually occur during the first 2 weeks of treatment. Fourth, some data suggest the existence of a mutation resulting in a phenotype combining QT prolongation (LQT3 subtype) and Brugada syndrome. 41 The use of Class 1A antiarrhythmic agents in patients with the Brugada syndrome who carry such a mutation could have deleterious consequences. In the authors' experience, however, no patient with Brugada syndrome treated with quinidine or disopyramide developed any abnormal QT prolongation requiring drug discontinuation. Finally, the last limitation is that the last decade has shown a marked decline in popularity of antiarrhythmic drug therapy in the medical community after the publication of the Cardiac Arrhythmia Suppression Trial (CAST) results. This is in addition to the fact that quinidine is frequently viewed by many physicians (especially the youngest ones) as an "old-generation" medication with severe potential proarrhythmic effects.
High Risk Asymptomatic Patients
Asymptomatic patients include two groups of patients. The first group is represented by patients in whom the ECG that discloses the Brugada sign is performed for routine reasons such as a workup prior to surgery or sport license or screening for insurance. The second group is represented by patients who have a Brugada-type ECG discovered following the occurrence of SCD or aborted SCD in a family member. The prognosis of asymptomatic patients is debated. Takenaka et al. 42 reported no major cardiac events in 11 asymptomatic patients with the Brugada sign during a mean follow-up of almost 4 years. In contrast, Brugada et al. 8 reported a 14% event rate in a large cohort of asymptomatic patients after a mean follow-up period of only 27 6 29 months after recognition of the abnormal ECG. In a recent study 43 
Role of Electrophysiological Testing
Brugada et al. 39 showed that electrophysiological testing is useful in the risk stratification of asymptomatic individuals with the Brugada sign. In the largest study (n 5 136) of asymptomatic patients published to date, they found that (1) 33% of these patients had inducible sustained ventricular tachyarrhythmias, (2) individuals who subsequently developed a first arrhythmic event had a longer H-V interval compared with individuals who remained asymptomatic (59 6 6 vs 48 6 11 ms, respectively, P 5 0.04), and (3) while 13% of inducible asymptomatic individuals developed an arrhythmic event, only 1% of noninducible individuals suffered such an arrhythmic event during follow-up.
Using programmed ventricular stimulation in the stratification of the arrhythmic risk should thus be encouraged for two reasons. First, patients without inducible arrhythmias can be reassured since only 1 (0.9%) arrhythmic event occurred in a noninducible patient with spontaneously abnormal ECG. 8, 39 Second, patients with inducible arrhythmias can be recommended to ICD therapy or electrophysiologically guided therapy with quinidine, like for the symptomatic patients. At the present time and although the task force on management of asymptomatic Brugada patients talks about controversial approaches, 6 the vast majority of electrophysiologists have adopted the same approach than for symptomatic patients, recommending ICD therapy in patients who have inducible sustained PVT/VF. Based on the arguments detailed above, the authors believe it practical to consider electrophysiologically guided pharmacologic therapy in asymptomatic high risk young individuals in whom the longterm complications of ICD therapy are likely to be encountered. Their own preliminary results in 12 high risk asymptomatic patients with the Brugada sign who were treated with quinidine according to electrophysiological testing have shown beneficial effects similar to those observed in symptomatic patients (Belhassen and Leenhardt, unpublished data). These findings and observations lend support to the use of quinidine as an alternative to ICD therapy in the prophylaxis of arrhythmic events and suggest the need for appropriate clinical trials.
Conclusions
The extraordinary efficacy of ICD in preventing sudden death in all high risk populations including patients with the Brugada syndrome has diminished the urgency of finding therapeutic alternative. Taking into account the beneficial electrophysiological and clinical effects of quinidine observed in a small number of patients with the Brugada syndrome 25 and the antiarrhythmic effectiveness in experimental models, 33, 35 further studies of oral quinidine or other I to blockers, like tedisamil, in patients with the Brugada syndrome should be encouraged. Only if the results are confirmed by others could randomized clinical trials comparing ICD therapy and quinidine be considered. One of these studies could be a comparison of ICD with electrophysiologically guided therapy with quinidine or other I to blockers in cardiac arrest survivors and asymptomatic high risk patients with inducible sustained tachyarrhythmias. Another could be a randomized study (placebo vs I to blockers) in patients already implanted with an ICD who have been experiencing relatively frequent events. With any of these scenarios, and in contrast to that has been observed in patients with organic heart disease, the long-term prognosis of patients with the Brugada syndrome is expected to be good in both arms and, therefore, a long study period may be necessary before differences (if any) between the two treatments is detected. At the present time, the authors' policy in the Tel-Aviv Medical Center is to offer electrophysiological drug-responder patients the choice of ICD or medical therapy following an objective and comprehensive discussion of the advantages and disadvantages of both therapy modes. Patients who prefer the medical therapy option should undergo repeat electrophysiological testing on medications every 5 years to confirm the initial beneficial results. The authors believe that there is a place for antiarrhythmic drug therapy in selected patient populations with the Brugada syndrome like young patients, patients who refuse the ICD option, or those who suffer from device related complications. Absolute requirements for this medical option (besides the efficacy of antiarrhythmic therapy at repeat electrophysiological study) include an excellent patient tolerance to medications and his/her commitment to long-term pharmacologic therapy.
